Use of the GSK MenACWY-CRM/MenB-4C Pentavalent Meningococcal Vaccine Among Persons Aged ≥10 Years - Recommendations of the Advisory Committee on Immunization Practices—United States, 2025

Sep 30, 2026

Meningococcal disease is a serious bacterial infection caused by Neisseria meningitidis, with serogroups B, C, W, and Y accounting for most cases in the United States. The report reviews licensed vaccines targeting different serogroups, including MenACWY and MenB products, and the pentavalent MenABCWY vaccine (MenACWY-TT/MenB-FHbp and the newer MenACWY-CRM/MenB-4C). It summarizes evidence supporting ACIP recommendations for when MenACWY-CRM/MenB-4C may be used, including dosing and clinical guidance for specific age groups and increased-risk conditions.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages8

Reading Time20 min

AccessFree to download

Abstract

Introduction

Background on meningococcal disease and risk factors

ACIP recommendations for MenACWY and MenB

Update for pentavalent MenABCWY (MenACWY-CRM/MenB-4C)

Box. Meningococcal vaccination recommendations—Advisory Committee on Immunization Practices, United States, 2025

Morbidity and Mortality Weekly Report Use of the GSK MenACWY-CRM/MenB-4C Pentavalent Meningococcal Vaccine Among Persons Aged ≥10 Years: Recommendations of the Advisory Committee on Immunization Practices—United States, 2025 Avnika B. Amin, PhD1,2; Jennifer P. Collins, MD 1; Xiaoyu Dong, PhD3; Andrew J. Leidner, PhD3; Jamie Loehr, MD4; Charlotte A. Moser, MS5; Lucy A. McNamara, PhD 1 Abstract Meningococcal disease is a serious bacterial infection caused by Neisseria meningitidis. Serogroups B, C, W, and Y cause the majority of cases of this disease in the United States. Theseserogroups are targeted by different meningococcal vaccines available in the United States. Two quadrivalent (serogroups A, C, W, and Y) meningococcal conjugate vaccines (MenACWY)(MenACWY-CRM [Menveo, GSK] and MenACWY-TT [MenQuadfi, Sanofi Pasteur]) and twoserogroup B meningococcal vaccines (MenB) (MenB-4C [Bexsero, GSK] and MenB-FHbp [Trumenba, Pfizer]) are licensed for use in the United States and recommended by CDC’s Advisory Committee on Immunization Practices (ACIP). Indications forMenACWY and MenB vaccination have not changed since indications for their use were published in 2020. A pentavalent (serogroups A, B, C, W, and Y) meningococcal vaccine (MenABCWY) (MenACWY-TT/MenB-FHbp [Penbraya, Pfizer]) has been licensed and recommended for use since October 2023. On February 14, 2025, the Food and Drug Administration licensed a second pentavalent MenABCWY vaccine (MenACWY-CRM/MenB-4C [Penmenvy, GSK]) for prevention of invasive disease caused by N. meningitidisserogroups A, B, C, W, andY in persons aged 10–25 years, the same indication for which MenACWY-TT/MenB-FHbp is licensed. On April 16, 2025, ACIP recommended that MenACWY-CRM/MenB-4C maybe used when both MenACWY and MenB are indicated atthe same visit for 1) healthy persons aged 16–23 years (routine schedule) when shared clinical decision-making favors administration of MenB vaccine and 2) persons aged ≥10 years who are at increased risk for meningococcal disease (e.g., because of persistent complement deficiencies, complement inhibitor use, or functional or anatomic asplenia). Different manufacturers’serogroup B–targeting vaccines are not interchangeable; therefore, when MenACWY-CRM/MenB-4Cis used, MenB-4Cshould be used for the other MenB doses. This report summarizes evidence considered for these recommendations and provides clinical guidance for the use of MenACWY-CRM/MenB-4C. Introduction Meningococcal disease, caused by Neisseria meningitidis, is a serious bacterial infection that can cause invasive or noninvasive disease. Serogroups B, C, W, and Y cause the majority of cases of meningococcal disease in the United States ( 1) . Risk factors for meningococcal disease include anatomic or functional asplenia, persistent complement component deficiencies, use of complement inhibitors (e.g., eculizumab or ravulizumab), HIV infection, active or passive exposure to tobacco smoke, and recent upper respiratory tract infection ( 1). Persons living in crowded settings, such as college residence halls, and those who are close contacts of persons with meningococcal disease are also at increased risk for acquiring meningococcal disease (1). CDC’s Advisory Committee on Immunization Practices (ACIP) recommends administration of a single dose of quadrivalent (serogroups A, C, W, and Y) meningococcal vaccine (MenACWY) to persons aged 11–12 years, with a booster doseat age 16 years, as part of the routine childhood immunization schedule. For persons aged ≥2 months who are at increased risk for meningococcal disease because of certain medical conditions or other exposures, ACIP recommends a multiple-dose MenACWY series, with regular booster doses if the recipient remains at increased risk (Box) (2) . Two MenACWY vaccines (MenACWY-CRM [Menveo, GSK] and MenACWY-TT [MenQuadfi, Sanofi Pasteur]) are licensed and recommended for use in the United States. In addition, ACIP recommendsserogroup B meningococc

FAQs

What vaccine products are covered for preventing meningococcal disease in this report?

The report covers quadrivalent MenACWY vaccines and two-dose MenB vaccines, as well as the pentavalent MenABCWY options including MenACWY-TT/MenB-FHbp and MenACWY-CRM/MenB-4C.

When does ACIP recommend using MenACWY-CRM/MenB-4C?

ACIP recommends MenACWY-CRM/MenB-4C may be used when both MenACWY and MenB are indicated at the same visit, including for healthy persons aged 16–23 years when shared clinical decision-making favors MenB administration and for persons aged ≥10 years at increased risk.

Are MenB vaccines from different manufacturers interchangeable?

No. The report states that serogroup B–targeting vaccines from different manufacturers are not interchangeable, so when MenACWY-CRM/MenB-4C is used, the MenB-4C product should be used for the other MenB doses.

Sep 30, 2026

Uploaded by PakDamar76